Updated Nov. 28, 2011 at 6:30 a.m.

Premium Lock Pozen sells royalty rights to migraine drug for $75M

Published: 2011-11-26 08:56:00
Updated: 2011-11-28 06:30:56

Treixmet Treximet

Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan....

Read More
Read More

Copyright 2014 MedCity. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll